The clinical and hormonal phenotype of types II and IV is similar to that of patients with sporadic PA. Another original article (Liu et al.) focused on the evaluation of postoperative management of ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The First International Symposium on Pheochromocytoma ... Localization studies should only follow reasonable clinical evidence of a tumor. Preoperative pharmacologic blockade of circulatory ...

Genes that are as yet unidentified will probably be found to cause hereditary pheochromocytoma or paraganglioma and increase the proportion of hereditary cases above that which has been already ...

Hallmark symptoms of Cushing disease, including abdominal striae and facial rounding, were more common among younger patients than older patients.

Here's what to know about flu symptoms in 2025, how to tell if it's something else, and how to protect yourself: But there are some differences. COVID-19 can show up later than the cold or flu ...

Industry giants like Takeda Pharmaceuticals, Pfizer, Novartis, and Bayer are revolutionizing treatment landscapes, paving the way for enhanced patien ...